(Zero Hedge)—Nissan plans to cut 1,500–2,000 U.S. jobs and reduce production by 25% as part of a strategic review, according to GuruFocus.
It aims to close a production line at its Smyrna, TN plant by April and another at its Canton, MS plant later in the year. The company is reviewing its EV production and investment strategy.
Spokesperson Shiro Nagai stated the reports are unofficial, and Nissan declined further comment. However, it wouldn’t be an unreasonable move for the automaker which has struggled in recent years and is in the midst of considering a merger.
Recall back in late December we wrote that the struggling automaker was considering a tie-up with Honda that would make it the world’s third largest automaker.
Facing competition from EV leaders like Tesla and China’s BYD, Japanese automakers are uniting to cut costs and accelerate their transition to electric vehicles.
Honda’s president, Toshihiro Mibe, stated last month that the companies plan to form a joint holding company, maintaining their brands while Honda leads management. A merger agreement is targeted for June, with the holding company expected to list on the Tokyo Stock Exchange by August 2026.
There is still to study and discuss, Mibe said. He commented: “Frankly speaking, the possibility of this not being implemented is not zero.”
“We have come to the realization that in order for both parties to be leaders in this mobility transformation, it is necessary to make a more bold change than a collaboration in specific areas,” he added.
AP writes that a potential merger between Honda, Nissan, and Mitsubishi could create an automotive giant valued at over $50 billion, helping them compete with industry leaders like Toyota and Volkswagen.
What Would You Do If Pharmacies Couldn’t Provide You With Crucial Medications or Antibiotics?
The medication supply chain from China and India is more fragile than ever since Covid. The US is not equipped to handle our pharmaceutical needs. We’ve already seen shortages with antibiotics and other medications in recent months and pharmaceutical challenges are becoming more frequent today.
Our partners at Jase Medical offer a simple solution for Americans to be prepared in case things go south. Their “Jase Case” gives Americans emergency antibiotics they can store away while their “Jase Daily” offers a wide array of prescription drugs to treat the ailments most common to Americans.
They do this through a process that embraces medical freedom. Their secure online form allows board-certified physicians to prescribe the needed drugs. They are then delivered directly to the customer from their pharmacy network. The physicians are available to answer treatment related questions.
